IMEIK is a leading Chinese biomedical soft tissue repair materials manufacturer.
IMEIK, founded in 2004, has been developed based on the research, development, and transformation of biomedical soft tissue repair materials. The founder is Jian Jun. Listed on the Shanghai Stock Exchange in September 2020, the company's major shareholders are Jian Jun, Ningbo Zhixingjun Investment Management Limited Partnership, and GANNETT PEAK LIMITED. Rivals with the direct and indirect competition with IMEIK include Haohai Biological, Bloomage BioTech.
Malaysia will consider reducing and exempting taxes from the agricultural and food sectors.
"Strange fire technology" obtained tens of millions of yuan of angel round financing
China VC Investment List Q4 2022 – Healthcare
For healthcare, we at EqualOcean have identified 20 companies worth watching in Q4 identified by proceedings. We select venture capital investments of over CNY 200 million on average or the equivalent value in USD in a single round.
Jan 05, 2023 06:55 PM
Aimeike signs distribution cooperation framework agreement with South Korea huons BP
Luoxin pharmaceutical: delayed disclosure of the first quarter report of 2022
2022 China AI Health 30 Report
The steel sector strengthened significantly
Baijiu plate strength, mouth cellar line exceeds 10%
AMEC: the capital increase and acquisition of part of the equity of hoons biopharma in South Korea have been completed
Xinhua III of Ziguang Co., Ltd. won the first place in China's 200g / 400g switch market share in 2021h1
Artificial Cardiac Company CoretechMed Raises Nearly CNY 200 Mn in Series C+
In the past five years, China's ventricular assist technology (i.e., "artificial heart") has developed rapidly, and three domestic implantable ventricular assist devices (LVADs) have been approved and marketed by the State Drug Administration, and another one is in the marketing declaration stage. The number of LVAD implantations has increased yearly, with a total of 363 LVAD implantations performed in 70 hospitals, a rapid increase.
Apr 17, 2023 05:12 PM
20 Chinese Companies to Watch in Q1 2023– Healthcare+
Editor's note: We at EqualOcean tracked the major funding rounds or industry events that took place in China’s healthcare space in Q1 2023. The following is a list of deals that we have selected for you, based on a number of criteria, including the funding amount, the financial backers, the activity level and the segments in which the startups operate.
Apr 07, 2023 01:39 PM
The investment banking business was strictly supervised, and seven securities companies received fines
The first batch of "Mao" concept achievements were released, with a year-on-year growth of more than 50%
The medical and American plate rose sharply
Dynamic Biosystems Snags Nearly CNY 100 Mn in Series A+
Dynamic Biosystems is a single cell and space multi-omics technology platform enterprise. The company focuses on exploring the huge potential in the fields of precision medicine of tumor, eugenics and fertility, and drug discovery, and is committed to promoting precision medicine to the era of single cell and space omics, helping life science and clinical medicine.
Feb 06, 2023 07:25 PM
Opportunities and Challenges Hidden in the CGT Industry in China
CGT (Cell and Gene Therapy) is a sector with high growth potential. CAR-T, as one of the main CGT currently, presents great value for both doctors and patients. This article showcases the industry pain points and opportunities faced in the CAR-T sub-sector.
Jan 17, 2023 05:48 PM
AMEC: the net profit in the first half of the year was 425 million yuan, a year-on-year increase of 188.86%
Yimei concept stocks weakened in early trading, and Huaxi biology fell more than 10%
Skyworth Digital: at present, the order volume of mini LED is sufficient and the production capacity is guaranteed
Aimike's reply to the letter of concern: after obtaining the equity of huons bio, it will not have a significant adverse impact on the company's production and operation